Edwards Heart Valve Snags Extra Patent Review Time
Published Date: 6/25/2025
Notice
Summary
The FDA has set the official review period for the EDWARDS SAPIEN 3 ULTRA RESILIA heart valve device, helping the makers apply for extra patent time. This means the company can potentially extend their patent, giving them more time to protect their invention and possibly earn more money. Patients and competitors should watch for changes in patent status and market availability.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA Sets Review Period for Valve
The FDA has determined the regulatory review period for the EDWARDS SAPIEN 3 ULTRA RESILIA premarket approval supplement (PMA 140031, S-141). This determination allows the device maker to submit applications to the U.S. Patent and Trademark Office to seek an extension of a patent that claims this medical device.
Patients, Competitors Should Watch
The notice says patients and competitors should watch for changes in the device's patent status and market availability after the FDA set the review period for EDWARDS SAPIEN 3 ULTRA RESILIA (PMA 140031, S-141). Changes in patent status could affect who sells the device and how broadly it is available.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in